Alterity completes 50-for-1 share consolidation
Alterity Therapeutics has completed a consolidation of its issued capital on a fifty (50) to one (1) basis, as previously approved by shareholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alterity Therapeutics has completed a consolidation of its issued capital on a fifty (50) to one (1) basis, as previously approved by shareholders. After the consolidation, the company has 217,508,862 ordinary fully paid shares on issue, along with multiple listed and unlisted option series with various expiries and exercise prices.
The company confirms post-consolidation holdings for shareholders and option holders, with any fractional entitlements rounded up to the nearest whole security. Normal T+2 trading in the consolidated shares has commenced on the ASX under code ATH. Alterity remains a clinical-stage biotechnology company focused on Multiple System Atrophy, preparing to initiate a Phase 3 pivotal trial for its lead asset ATH434.
Insights
Alterity finalizes a 50-for-1 reverse split, resetting its capital base without raising cash.
Alterity Therapeutics has implemented a fifty (50) to one (1) consolidation of its issued capital, resulting in 217,508,862 ordinary shares outstanding and a revised suite of listed and unlisted options with updated counts but unchanged economic terms per option.
This type of consolidation, often called a reverse split, is primarily mechanical: it reduces the share count and typically increases the trading price per share without altering the company’s underlying value. The filing does not indicate any new financing; it simply clarifies the post-consolidation capital structure and confirms that normal ASX trading in code ATH has commenced.
Alongside the capital change, the company reiterates its focus on developing ATH434 for Multiple System Atrophy, noting Phase 2 efficacy results and preparation for a Phase 3 pivotal trial. Future updates in company communications may provide more detail on the Phase 3 design and regulatory interactions.
Key Figures
Key Terms
consolidation of the Company’s issued capital financial
T+2 settlement basis financial
Phase 3 pivotal trial medical
randomized, double-blind, placebo-controlled Phase 2 clinical trial medical
Multiple System Atrophy (MSA) medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What capital change did Alterity Therapeutics (ATHE) complete in June 2026?
What is Alterity Therapeutics’ lead clinical program after the capital consolidation?
Did the Alterity Therapeutics capital consolidation affect its options?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Completion of Consolidation |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: June 12, 2026
Exhibit 99.1
Completion of Consolidation of Capital
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 June 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that the consolidation of the Company’s issued capital on a fifty (50) to one (1) basis, as approved by shareholders at the General Meeting on 29 May 2026, has now been completed.
The Company’s post-consolidation capital structure is as follows:
|
ASX CODE |
QUOTED SECURITIES |
NUMBER |
|
ATH |
Ordinary fully paid shares |
217,508,862 |
|
ATHO |
Option expiring 31-Aug-2026 ex $0.50 |
18,624,729 |
|
ATHOA |
Option expiring 26-Feb-2027 ex $1.40 |
24,446,043 |
|
ASX CODE |
UNQUOTED SECURITIES |
NUMBER |
|
ATHAA |
Option expiring 13-Mar-2029 ex $0.20 |
403,334 |
|
ATHAAE |
Option expiring 29-Nov-2026 ex $1.875 |
200,000 |
|
ATHAAG |
Option expiring 29-Nov-2026 ex $1.19 |
230,000 |
|
ATHAAH |
Option expiring 19-Dec-2026 ex $0.525 |
160,000 |
|
ATHAAK |
Option expiring 30-Dec-2027 ex $0.50 |
3,400,000 |
|
ATHAAL |
Option expiring 09-Jan-2031 ex $0.40 |
360,000 |
|
ATHAAM |
Option expiring 13-Jan-2031 ex USD 0.285 |
870,000 |
|
ATHAB |
Option expiring 13-Mar-2029 ex USD 0.155 |
1,250,000 |
|
ATHAC |
Option expiring 21-Mar-2029 ex USD 0.15 |
800,004 |
|
ATHAD |
Option expiring 01-Jul-2030 ex $0.50 |
300,000 |
|
ATHAE |
Option expiring 08-Aug-2030 ex $0.65 |
230,000 |
|
ATHAF |
Option expiring 08-Aug-2030 ex USD 0.43 |
6,248,004 |
|
ATHAG |
Option expiring 26-Mar-2031 ex USD 0.285 |
1,230,000 |
|
ATHAJ |
Option expiring 15-Apr-2031 ex USD 0.302 |
4,245,000 |
|
ATHAK |
Option expiring 15-Apr-2031 ex $0.45 |
540,000 |
Where the consolidation process resulted in a fraction of a share, any fractional entitlements have been rounded up to the nearest whole number (to a minimum of 1 security).
Holding statements have been despatched to all shareholders and option holders advising them of their holdings on a post-consolidation basis.
Normal trading (on a T+2 settlement basis) commenced today, Friday 12 June, under ASX code “ATH”.
Authorised for release by the Board of Directors of Alterity Therapeutics Limited.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytx.com.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520